This study investigated changing levels of serum oxidant/antioxidant with chemotherapy and their relation to treatment in 34 Hodgkin's lymphoma patients. The patient population consisted of 19 males and 15 females. Mean age was 30.41 ± 12.08 years. All patients received the adriamycin, bleomycin, vincristine and dexamethasone (ABVD) treatment protocol. Blood samples were taken before treatment, and on days 1 and 7 during treatment for measurement of superoxide dismutase (SOD), glutathione peroxidase (GSH-Px), catalase (CAT), malondialdehyde (MDA), nitric oxide (NO) and enzyme activities. After ABVD treatment, mean free radical levels were increased and antioxidant levels were significantly decreased in the serum. ABVD treatment results in an increase of free radical levels and a decrease of antioxidant levels in the serum of patients with Hodgkin's lymphoma.
Introduction
Free radicals are molecules made highly reactive as a result of the presence in them of atoms with one or more unshared electrons. In general, free radicals form following the breakdown of a covalently bound molecule where each part takes one of the shared electrons, with the addition of or loss of an electron. Conversely, in biological systems, free radicals form mostly by electron transfer. 1 These molecules are produced in large quantities during the regular cell cycle. Since molecular oxygen is present in large quantities, it can easily travel within cells, and its atomic structure forms free radicals readily. In the context of the human body the term 'free radicals' means free oxygen radicals. 2 Free oxygen radicals induce breaks in DNA and chromosomes, and may contribute to oncogene activation. 3, 4 Many drugs used in cancer chemotherapy (such as doxorubicine and bleomycin) form free radicals as a result of their metabolic activities. 5, 6 A number of defence mechanisms are present in the body to prevent the formation of reactive oxygen species (ROS) and the damage resulting from their presence. Plasma and tissue antioxidants are classified as primary, secondary and tertiary antioxidant defences. Primary defence is the best-defined prevention mechanism against free radicals. It prevents radical formation by binding iron atoms to high-affinity positions in the protein molecules in the extracellular matrix. The mechanism is similar to that involving lactoferrin and transferrin. Secondary defence involves transport and inactivation of existing ROS. Enzymes such as superoxide dismutase (SOD), catalase (CAT) and glutathione peroxidase (GSH-Px), as well as low-molecular structures like vitamin E and ascorbate, react in this manner. Tertiary defence involves the transport and repair of molecules subjected to oxidative damage and is important for DNA. 7 This study looks at the effects of adriamycin, bleomycin, vincristine and dexamethasone (ABVD) treatment on serum nitric oxide (NO), malondialdehyde (MDA), SOD, CAT, and GSH-Px enzyme levels in patients with Hodgkin's lymphoma.
Materials and methods
The study population consisted of patients diagnosed with Hodgkin's lymphoma between August 2003 and March 2004 at the Haematology Department of Inonu University, Turgut Ozal Medical Centre. Patients gave informed consent and ethics committee approval was obtained. All patients received the ABVD treatment protocol. Blood samples were taken before treatment, and on days 1 and 7 during treatment.
SOD ACTIVITY DETERMINATION
The activity of SOD was measured spectrophotometrically as described by Sun et al. 8 In summary, xanthine-xanthine oxidase was utilized to generate a superoxide flux. Reduction of nitrobluetetrazolium (NBT) by superoxide anion to blue formazan was determined at 560 nm. One unit of enzyme activity was defined as the amount of protein causing 50% inhibition in NBT reduction by superoxide. Results were expressed in units/g of haemoglobin.
GSH-PX ACTIVITY DETERMINATION
The activity of GSH-Px in plasma was measured spectrophotometrically as described by Paglia and Valentine. 9 The enzyme reaction was initiated by addition of H 2 O 2 and the rate of NADPH oxidation was followed at 340 nm. One unit of GSH-Px was expressed as the amount of enzyme that oxidizes 1 mmol NADPH/min. Results were expressed in units/g of haemoglobin.
CAT ACTIVITY DETERMINATION
The catalytic activity of catalase was determined as described by Aebi. 10 The decomposition of the substrate H 2 O 2 was monitored spectrophotometrically at 240 nm. One unit of enzyme was defined as 1 mmol H 2 O 2 utilized per minute. Enzyme activity was expressed in K/g of haemoglobin.
MDA DETERMINATION
The levels of MDA were determined by the method of Wasowicz et al. 11 using a Hitachi Model 4010 spectrofluorometer (Hitachi model 4010, Tokyo, Japan). The amount of coloured complex obtained by the reaction of MDA and thiobarbituric acid was determined, employing wavelengths of 525 and 547 nm for excitation and emission, respectively. The concentration of MDA was expressed as µmol/l of plasma.
NITRATE AND NITRITE LEVEL DETERMINATION
Since NO is unstable and is rapidly converted into nitrates and nitrites, the NO concentration was determined in terms of nitrate and nitrite levels. Direct and total nitrite levels in plasma were determined with the Greiss reaction as described by Green et al. 12 Nitrate concentration was calculated by subtracting direct nitrite from total nitrite. Results were expressed as µmol/l of plasma.
STATISTICAL ANALYSIS
Mean and standard deviations were calculated for each parameter. Comparison of means was calculated by analysis of variance (ANOVA), and the minimum level of significance was defined as P < 0.05.
Results
Of the 34 patients included in the study, 19 were male and 15 female, with a mean age of 30.41 ± 12.08 (range, 18 -63) years. On days 1 and 7 of ABVD treatment, SOD, CAT and GSH-Px activities had decreased while NO and MDA serum levels had increased significantly (P < 0.001), compared with pre-treatment levels. Serum oxidant and antioxidant levels of study patients are shown in Table 1 .
Discussion
Sources of free oxygen radicals can be biological, intracellular or toxic material. Following induction, phagocytic white blood cells, which are considered a biological source, release their lysosomal contents and form reactive oxygen metabolites. 13 These metabolites (ROS) have important effects on cellular growth, development and differentiation. They are known to play a role in atherosclerosis, cancer, ageing and inflammation pathogenesis. 14 -16 Studies have shown that factors affecting tumour formation induce free radical production in most cells. These factors induce tumour formation and development as is demonstrated by their effects on initiation, promotion, and progression phases of carcinogenesis. 17 Free oxygen radicals cause breaks in DNA and chromosomes, and activate oncogenes. 3, 4 They destroy the phenotypic and genotypic structure of cells producing changes varying from mutation to neoplasia. 18 Many drugs used in cancer chemotherapy, such as doxorubicine and bleomycin, form free radicals as a result of metabolic activities. 5, 6 Bleomycin, as it has a glycopeptide antibiotic structure, is part of the ABVD treatment protocol for Hodgkin's Oxidant/antioxidant parameters and chemotherapy in Hodgkin's lymphoma lymphoma. It inhibits cancer cell proliferation by single-or double-strand breakage in DNA and induces apoptosis. In addition to these DNA breaks, bleomycin plays a role in MDA production. MDA reacts with thiobarbituric acid (TBA) and results in more DNA breakage, an important cytotoxic effect. 19 Cells have antioxidant defence mechanisms against free radical formation which prevent or limit their harmful effects. Key enzymes in antioxidant defence mechanisms are SOD, CAT and GSH-Px, while important antioxidant materials are tocopherol, retinol and ascorbic acid. 20, 21 These antioxidant enzymes undergo modification during carcinogenesis and after tumour formation. 22 Disequilibrium in the antioxidant defence mechanism of the patient increases the cells' sensitivity to free radicals. 23 Low levels of antioxidant enzymes result in accumulation of free oxygen radicals with consequent damage to DNA, RNA, lipids and proteins, as well as perhaps eventually having an effect on cancer cells. 24 In a study comparing serum MDA, GSH-Px and SOD levels prior to treatment in 20 male patients recently diagnosed with Hodgkin's lymphoma with 30 healthy male controls, Guven et al. 20 showed that Hodgkin's lymphoma patients had significantly higher levels of MDA and SOD, and significantly lower levels of GSH-Px. They suggested that an increase in MDA levels -a product of free oxygen radical breakdown -contributes to malignant tumour development. High levels of superoxide and hydrogen peroxide concentrations may increase the activity of SOD in cancerous tissue. In our study, while the mean MDA level before the start of chemotherapy was 3.82 ± 0.38, it increased on day 1 after the start of chemotherapy (4.30 ± 0.28) and reached its highest level on day 7 (4.90 ± 0.46). Before the start of chemotherapy, both SOD (1331.62 ± 90.21) and GSH-Px (1.29 ± 0.05) levels were found to be high. On day 7 after the start of chemotherapy, MDA levels increased significantly, while SOD and GSH-Px levels showed significant decrease (P < 0.001).
In a study comparing 24 cases with malignant tumours in the head and neck region with 17 healthy subjects (the control group), pre-treatment red blood cell MDA levels and the SOD, CAT and GSH-Px enzyme activities were assessed. 24 Red blood cell MDA and SOD levels in the patients were found to be higher compared with the control group, while CAT activities were lower. There was no statistically significant difference in GSH-Px activities in both groups. It was postulated that higher MDA levels in the patients in comparison with the control group played a role in the development of head and neck malignancies by causing tissue damage. In our study, MDA levels showed significant increases (P < 0.001) after the start of chemotherapy compared with initial values, while SOD, CAT and GSH-Px levels were significantly reduced (P < 0.001). An increase in the level of free radicals present in tumour cells may play a role in tissue damage and may promote the occurrence of untoward side-effects resulting from chemotherapy.
In a study of 14 patients diagnosed with multiple myeloma, free radical levels were compared between pre-vincristine-adriamycindexamethasone (VAD) treatment and post-VAD treatment (days 3, 7, 10 and 28). 25 Posttreatment SOD, CAT, GSH-Px, NO and MDA serum levels were higher compared with those before treatment. In the days following VAD treatment, CAT and GSH-Px serum levels were decreased, while SOD activity started to increase after day 10. The lowest levels of MDA and NO were recorded on day 7 and day 10, respectively. During follow-up, CAT Oxidant/antioxidant parameters and chemotherapy in Hodgkin's lymphoma and GSH-Px levels continued a steady decline. On day 28 post-treatment, all variables were measured and were below their pre-treatment values. In our study, post-ABVD treatment (day 7) MDA and NO levels were significantly increased compared with day 0, while SOD, CAT and GSH-Px levels were significantly decreased in Hodgkin's lymphoma patients.
In a cisplatin-induced organ toxicity study, 48 cancer patients were investigated. All patients were administered combination therapies containing cisplatin. Twenty-five patients were given additional vitamin C, E or selenium, while the remaining 23 were evaluated as a placebo group. MDA, vitamin C, E and selenium levels were compared both pre-treatment and on day 7 post-treatment. When autotoxicity and nephrotoxicity were considered as the primary outcomes, no statistically significant difference was found between the two groups, even though lowered serum MDA levels were observed in the antioxidant-receiving group. Inability of antioxidants to protect against cisplatininduced toxicity was attributed to noncompliance of patients and/or insufficient antioxidant treatment. 26 The desirable treatment for malignant tumours would be an agent that has a preferable effect on tumour cells without causing side-effects on healthy cells. Such an ideal agent does not yet exist. Ionising radiation and drugs like antracycline and bleomycin produce free radicals that damage the tumour but, at the same time, such radicals are also responsible for the agents' side-effects. 27, 28 Both radiation and chemotherapy agents induce free radical formation in healthy cells as well as in tumour cells. High levels of free radicals start a deadly chain of reactions in the cell and kill it by deactivating vital enzymes, proteins and other elements that are important for cell survival. 18 In conclusion, after ABVD treatment we observed an increase in mean serum free radicals and a significant decrease in antioxidant levels, which constitute the body's defence mechanism. Many drugs used in cancer chemotherapy form free radicals as a result of their metabolic activities. 5, 6, 27, 28 On the other hand, tumour regression itself induces free radicals. 25 We thought that the change in oxidant/antioxidant parameters could be due to both the direct effect of chemotherapy and the indirect effect of tumour regression. We observed regression in all patients but only from the first course of chemotherapy protocol at this stage. We did not quantify the contribution arising from the patients' response. As a result, we cannot say whether or not there is a relationship between response and change in oxidation parameters. These results suggest that chemotherapy destroys the oxidant/antioxidant equilibrium in the body, which may in turn contribute to untoward effects and/or secondary malignancies. To assess these risks, studies involving long-term follow-up and greater numbers of patients are needed.
